Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
AstraZeneca (AZN) and Daiichi Sankyo announced the FDA has accepted a supplemental BLA and granted Priority Review for ENHERTU as post-neoadjuvant treatment for adult patients with HER2 positive early breast cancer with residual invasive disease. The PDUFA target date is July 7, 2026. DESTINY-Breast05 showed a 53% reduction in risk of invasive disease recurrence or death (HR=0.47) and a three-year IDFS of 92.4% versus 83.7% with T-DM1.
AstraZeneca (NYSE:AZN) announced FDA approval of CALQUENCE plus venetoclax as the first all-oral, fixed-duration (14-cycle, ~14-month) regimen for previously untreated adult CLL/SLL. The AMPLIFY Phase III trial showed 77% progression-free at 3 years vs 67% with chemoimmunotherapy; median PFS was not reached versus 47.6 months and risk of progression/death was reduced by 35% (HR 0.65; p=0.0038).
Safety was consistent with known CALQUENCE risks; no new safety signals identified.
AstraZeneca (AZN) and Daiichi Sankyo announced the EMA validated a Type II Variation application for ENHERTU as monotherapy for adults with HER2 positive early breast cancer with residual invasive disease after neoadjuvant therapy.
The submission is based on DESTINY-Breast05 phase 3 results showing ENHERTU reduced risk of invasive disease recurrence or death by 53% versus T-DM1 and begins CHMP scientific review toward potential EU approval.
AstraZeneca (NYSE: AZN) reported positive Phase III KALOS and LOGOS results showing BREZTRI Aerosphere (BGF 320/28.8/9.6μg) improved lung function and reduced severe asthma exacerbations versus dual ICS/LABA therapy.
In pooled analysis BREZTRI increased trough FEV1 by 76 mL and FEV1 AUC0-3 by 90 mL over 24 weeks; regulatory filings for asthma are under review.
AstraZeneca (NYSE:AZN) awarded $3.4 million through its Accelerate Change Together (ACT) on Health Equity initiative on February 11, 2026, funding 47 nonprofit programs across the US to advance healthcare access, nutrition, lung health and remove barriers to care.
The 2025 awards include 37 Community Solutions Challenge grants of $30,000 each (total $1.11M) and 10 National Strategic Collaborations totaling $2.3M; ACT contributions exceed $18 million to date.
AstraZeneca (NYSE:AZN) reported FY 2025 Total Revenue of $58,739m (up 8% CER) and Core EPS of $9.16 (up 11% CER). Product Revenue was $58,640m. Management declared a second interim dividend of $2.17, raising total FY dividend to $3.20 (up 3%).
FY 2025 included 16 positive Phase 3 readouts, 43 major-region approvals, guidance for mid-to-high single-digit Total Revenue growth and low double-digit Core EPS growth in FY 2026, and a $15bn China investment plan through 2030.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced the FDA has accepted the sBLA for DATROWAY (datopotamab deruxtecan-dlnk) and granted Priority Review for 1st-line treatment of unresectable or metastatic triple-negative breast cancer (TNBC) in patients ineligible for PD-1/PD-L1 inhibitors. The FDA action date is anticipated in Q2 2026 under Project Orbis.
Results from TROPION-Breast02 showed a median overall survival improvement of 5.0 months (HR 0.79; 95% CI 0.64-0.98; p=0.0291), a 43% reduction in risk of progression or death (HR 0.57; 95% CI 0.47-0.69; p<0.0001), ORR 62.5% and DoR 12.3 months versus chemotherapy.
AstraZeneca (AZN) and Daiichi Sankyo announced the sBLA for DATROWAY was accepted and granted Priority Review in the U.S. for first-line unresectable/metastatic triple negative breast cancer patients not eligible for immunotherapy.
The submission, reviewed under Project Orbis, is supported by TROPION-Breast02 results: median overall survival improved by 5.0 months (HR=0.79; p=0.0291), progression risk reduced by 43% (HR=0.57; p<0.0001), ORR 62.5% and DoR 12.3 months. PDUFA date: June 2, 2026.
AstraZeneca (NYSE/LSE/STO: AZN) began trading ordinary shares on the New York Stock Exchange on 2 February 2026, creating a harmonized global listing across New York, London and Stockholm. The company says this expands US investor access while maintaining LSE and STO listings and index inclusion.
AstraZeneca noted a >$10bn peak revenue opportunity from recent pipeline readouts and reiterated a 2030 ambition of $80bn annual revenue and launching 20 new medicines.
AstraZeneca (AZN) and Daiichi Sankyo announced that on January 19, 2026 the European Medicines Agency validated a Type II Variation application to expand marketing authorization for ENHERTU (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2 positive breast cancer. The validation starts the CHMP scientific review. The application is supported by the DESTINY-Breast09 phase 3 trial, which showed a statistically significant improvement in progression-free survival versus THP and was presented at ASCO 2025 and published in The New England Journal of Medicine. The companies noted a recent U.S. approval for this indication and said they will work with the EMA during review.